Press Releases

Creative Enzymes Launches Diamine Oxidase (Food-Grade) for Enhanced Food Safety and Digestive Health

CD Genomics Unveils Genotyping by Sequencing (GBS) -Revolutionizing Genomic Research

CD Genomics Redefines RNA Sequencing with Revolutionary Ultra Low RNA Sequencing Technology

CD BioGlyco Launches Anti-glycan Antibody Development Services to Advance Biomedical Research

CD Genomics Unveils Cutting-Edge DNA 6mA Sequencing Service for Epigenomic Research

Expanding Research Frontiers: CD Formulation Enables In Vitro Cytotoxicity Testing for Microspheres and Microneedles

MERCY BIOANALYTICS ADDS MARKETING AND PORTFOLIO MANAGEMENT LEADERSHIP TO SUPPORT DIAGNOSTIC TEST DEVELOPMENT AND COMMERCIALIZATION

Mercy BioAnalytics, Inc. - a pioneer in extracellular vesicle-based liquid biopsies for early cancer detection - added two executives in marketing and portfolio management as it continues rapid development of its novel test portfolio and looks ahead to commercialization.

Alfa Chemistry: Transforming Research Possibilities through Instrumental Analytical Reagents

NICE RECOMMENDS LILLY’S MIRIKIZUMAB (OMVOH ®▼) FOR THE TREATMENT OF ELIGIBLE ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

Mirikizumab is the first IL-23p19 targeted biologic recommended by NICE for use within NHS England and Wales for treating moderately to severely active ulcerative colitis in adults.1,2. In two randomised, double-blind, placebo-controlled phase 3 trials, LUCENT-1 and LUCENT-2, mirikizumab achieved primary and key secondary endpoints, including sustained clinical remission. Decreases in bowel urgency severity were observed as early as week 2 in patients treated with mirikizumab versus placebo in LUCENT-1.2 Mirikizumab has been recommended through the NICE cost-comparison process meaning NHS England and commissioning groups have agreed to provide funding to implement this guidance within 30 days from publication of the technology appraisal guidance (TAG) rather than the standard 90 days, providing faster access to a new treatment option for eligible adults living with moderately to severely active ulcerative colitis1

Precision BioLogic’s Factor VIII Deficient Plasma with VWF Now FDA-Cleared for Sale in U.S.

Precision BioLogic Inc., a leading developer of hemostasis diagnostic products, is pleased to announce FDA 510(k) clearance and the launch of our new cryocheck™ Factor VIII Deficient Plasma with VWF in the U.S. The latest in Precision BioLogic’s family of factor deficient plasmas, cryocheck Factor VIII Deficient Plasma with VWF is intended for use in clinical laboratories to identify factor VIII (FVIII) deficiency in human plasma and aid in the management of hemophilia A. It has normal levels of von Willebrand factor (VWF) but both FVIII antigen and activity levels of less than 1%. The importance of FVIII antigen levels in the performance of FVIII deficient substrates was demonstrated in a study presented at ISTH 2021. "CRYOcheck Factor VIII Deficient Plasma with VWF offers labs a readily available and reliable alternative to congenital FVIII deficient plasmas. In fact, the product has already gained significant traction within the hemophilia research and pharmaceutical manufacturing community," says Paul Empey, President & CEO of Precision BioLogic.

PathAI Announces Expansion of BioPharma Lab to Provide End-to-End Central Pathology and Histology Services

Capitalizing on the 30-year history of delivering high quality pathology services in the PathAI Diagnostics clinical laboratory (formerly known as Poplar Healthcare), PathAI offers biopharma partners a comprehensive, GCP/GCLP compliant histology and digital pathology lab to support prospective clinical trials across oncology, liver, and gastrointestinal indications.

BioIVT Webinar Will Discuss How to Manage Uncooperative Drugs in In Vitro Transporter Research

Dr. Joanna Barbara will present practical strategies to achieve definitive results when researching unstable, sticky, or insoluble compounds.

AVIA Launches Innovative AI Labs, AI Co-pilot for Digital Health Transformation

AVIA's newest AI-focused initiative aims to share practical application of AI to better inform - and transform - the healthcare industry

Alfa Chemistry Unveils Revitalized Strong/Weak Acid Cation Resin and Base Anion Resin Lineup

CD ComputaBio Unveils Cutting-Edge Advances in Antibody Drug Design and Development

CD ComputaBio Launches Revolutionary Antibody De Novo Design Service Pioneering Precision Medicine with AI

CD Formulation Demonstrates Expertise in CAR-T and CAR-NK Cell Development for Drug Delivery Systems

Daptomycin ReadyMade™ Solution to Power Up Spectrum and Microbiology Applications

Huateng Pharma to Attend CPHI Barcelona 2023

Huateng Pharma will be attending CPhI Worldwide, Booth 3C02, Hall 3.

ELRIG UK Establishes Engagement Strategy Work Group

The European Laboratory Research & Innovation Group (ELRIG) UK today announced the formation of its Engagement Strategy Work Group (ESWG). The group will provide strategic direction and guidance to help ensure the ELRIG community continues to grow and thrive. It aims to engage audiences in different ways, beyond face-to-face events, broadening access to high-quality science across a more diverse and inclusive network.